Robert Francomano
Geen lopende functies
Vermogen: 33 724 $ op 31-05-2024
Loopbaan van Robert Francomano
Eerdere bekende functies van Robert Francomano
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 14-03-2022 | 31-03-2024 |
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-09-2016 | 01-12-2021 |
Opleiding van Robert Francomano
Siena College | Undergraduate Degree |
University of Albany | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Beurs
- Insiders
- Robert Francomano
- Ervaring